Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/10/2009

EAST BRUNSWICK, N.J., Aug. 10 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today reported financial results for the three and six months ended June 30, 2009, ending the quarter with $76.6 million in cash and short-term investments, a reduction of $2.0 million from December 31, 2008. Excluding the receipt of the $29.0 million in cash from our registered direct offering in April 2009, our cash burn for the six months ended June 30, 2009 was $31.0 million, or approximately $5.0 million per month.

The net loss for the second quarter of 2009 was $54.8 million or $0.92 per basic and diluted share on total revenues of $0.7 million, compared with a net loss of $24.2 million or $0.45 per basic and diluted share on total revenues of $0.4 million for the second quarter of 2008. A significant portion of our net loss for the three months ended June 30, 2009 resulted from a non-cash charge of $35.8 million due to a valuation adjustment relating to warrants that we issued in connection with our April 2009 registered direct offering. On a non-Generally Accepted Accounting Principles (GAAP) basis, excluding the $35.8 million non-cash charge due to the valuation adjustment, our net loss for the second quarter of 2009 was $19.0 million, or $0.32 per basic and diluted share, compared with a GAAP net loss for the second quarter of 2008 of $24.2 million, or $0.45 per basic and diluted share.

As part of our April 2009 registered direct offering, we issued to investors 5.9 million shares of common stock and warrants to purchase up to 5.0 million shares of common stock. We account for the warrants as a liability and are required to record a mark-to-market valuation adjustment at the end of each financial reporting period. Because the value of our common stock price increased between the is
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Gift Card Network members ... in sustainable card material, are combining forces to ... as a sustainable gift card substrate. , The ... challenges and increase education and usage of these ... the reduction of carbon footprint and environmental impact ...
(Date:5/24/2013)... May 24, 2013 Let’s face it: very ... not uncommon for the majority of people to be uncomfortable ... due to a coffee addiction or simply genetics, yellowish or ... are so popular. , Herald Square Dental is ... effective whitening system: Venus White Max. , Teeth become ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... to the development of infantile myofibromatosis (IM)a disorder characterized ... tissuemay provide new therapeutic targets, according to researchers from ... findings, published in the American Journal of Human ... this debilitating disease, for which the only current treatment ... IM is an inheritied disorder that develops in infancy ...
(Date:5/24/2013)... Mike Stoler believes that there is much ... in New York. That’s why he hosts “Building ... TV. And that’s why he invited Robert Glazer, ... (ENTA)—the largest single specialty practice in the greater New ... audiology specialists and sub-specialists service communities throughout New York ...
Breaking Medicine News(10 mins):Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4
... , WEDNESDAY, Feb. 23 (HealthDay News) -- The main ... regain their ability to taste and enjoy food, according to ... could potentially lead to treatments to help some cancer patients ... to smell and taste food, which can cause them to ...
... a factory or at a rock concert, noise-induced hearing loss ... Researchers at Washington University School of Medicine in St. Louis ... in mice when given before they are exposed to loud ... hearing loss after noise exposure. While both drugs are ...
... - Understanding the genetics of bipolar disorder could lead ... with this disorder has been challenging. A ... brain protein called Piccolo in the risk for inheriting ... is a member of a protein family that includes ...
... percent of the world,s population is currently infected by hepatitis ... cirrhosis and liver cancer, and it,s the most frequent cause ... we have no traditional vaccine, but researchers at the University ... a vaccine, which provides future hope for medical protection from ...
... , WEDNESDAY, Feb. 23 (HealthDay News) -- People,s ... to stress, according to a new study. To reach ... make a speech in a laboratory in front of a ... responses were monitored during the speech, and they were later ...
... after having early-stage breast cancer, but they are at ... a new cancer, in either breast. Annual screening (a.k.a. ... but only scant evidence on screening outcomes supported this ... the American Medical Association , the most comprehensive relevant ...
Cached Medicine News:Health News:Pot Ingredient May Restore Appetite After Chemo 2Health News:2 drugs protect hearing better than 1 2Health News:A new clue to the genetics of bipolar disorder: Piccolo 2Health News:New vaccine technology protects mice from hepatitis C virus 2Health News:New vaccine technology protects mice from hepatitis C virus 3Health News:New vaccine technology protects mice from hepatitis C virus 4Health News:Screening mammograms catch second breast cancers early 2
(Date:5/24/2013)...  An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...
(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer").  On 20 May 2013, ...
(Date:5/23/2013)... 3SBio Inc. (NASDAQ: SSRX ... China -based biotechnology company focused on ... today that, at an extraordinary general meeting held ... favor of the proposal to authorize and approve ... dated February 8, 2013, among Decade Sunshine Limited, ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3